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ABSTRACT: Photoinduced antibacterial gold nanoparticles were developed as an alternative for the treatment of antibiotic resistant bacte-
ria. Thanks to the amoxicillin coating, they possess high in vivo stability, selectivity for the bacteria wall, a good renal clearance, and are com-
pletely non-toxic for eukaryotic cells at the bactericidal concentrations. A simple one-step synthesis of amoxi@AuNP is described at mild 
temperatures using the antibiotic as both reducing and stabilizing agent. Time-resolved fluorescence microscopy proved these novel nano 
photosensitizers, with improved selectivity, are bactericidal but showing excellent biocompatibility toward eukaryotic cells at the same dose 
(1.5 μg/mL) when co-cultures are analyzed. Their stability in biological media, hemocompatibility and photo-antibacterial effect against 
sensitive and antibiotic resistant Staphylococcus aureus were evaluated in vitro, while toxicity, renal clearance and biodistribution were studied 
in vivo in male Wistar rats. The use of these nanoparticles to treat antibiotic-resistant infections is promising given their high stability and 
cytocompatibility. 
Introduction 1 
Antibiotic resistant (AR) bacteria and the lethal infections they can cause 2 
are a subject of public concern.1-2 Indeed, the World Health Organisation 3 
(WHO) has described AR as “a problem so serious that it threatens the 4 
achievements of modern medicine”.3 Thus, there is an urgent need for the 5 
development of novel strategies and drugs. In recent years, nanoparticles 6 
have been tested as potential antibacterial agents; particularly, gold nano-7 
particles (AuNPs) were chosen to act as photosensitizers because of their 8 
inert nature and effectiveness in spite of their polymorphism and polydis-9 
persity.4 Further, AuNPs plasmons can absorb visible light,5 thus avoiding 10 
the use of highly energetic wavelengths that cause cell photodamage, 11 
proving useful for cancer treatment.6 Additionally, we have shown the 12 
photoinduced bactericidal properties of AuNPs utilizing green light, even 13 
on AR clinical strains.7-10 Thus, plasmon excitation of the AuNPs can pro-14 
duce highly reactive oxygen species (ROS) levels causing oxidative stress 15 
after 4 hours of Photodynamic Antimicrobial Chemotherapy (PACT), 16 
leading to bacterial death. Furthermore, in vitro studies suggest that these 17 
AuNPs are non-toxic for eukaryotic cells. These results stimulated the 18 
present work to explore the selectivity towards prokaryotic cells in cell co-19 
cultures and the biocompatibility and distribution of the particles in vivo.  20 
Many in vivo studies on the biodistribution and toxic effects of AuNPs show 21 
that they are controlled by the nanomaterial size, shape and coating.11-13 22 
The limited pore size of the endothelial wall in the tissue is the primary 23 
delivery barrier for nanoparticles but also allows selective accumulation in 24 
certain tissues. When nanoparticles are administered through intraperito-25 
neal (IP) or intravenous injection, a variety of serum proteins bind to their 26 
surface, which are recognized, internalized and carried to the liver or 27 
spleen.14 It is known that the majority of the AuNPs after IP injection are 28 
distributed to the liver and spleen in 2-3 hours,15 and that AuNPs had a fast 29 
blood clearance rate being mostly distributed in the liver, followed by the 30 
spleen and lungs.16 No matter the pathway used, AuNPs seemed to migrate 31 
into the circulatory system first, and subsequently distributed into tissues 32 
and organs; thus, mainly distributed by passive targeting.17 33 
It has been demonstrated that AuNPs can enhance their bactericidal prop-34 
erties when combined with antibiotics, such as vancomycin, aminoglyco-35 
side and amoxicillin, among others.18-23  Amoxicillin is a beta-lactam antibi-36 
otic24 and, like other penicillins, binds to and inhibits the carboxypeptidase 37 
and transpeptidase enzymes that are required for peptidoglycan biosynthe-38 
sis (Figure S1).25 The nitrogen-containing beta-lactam ring is designed to 39 
target the penicillin-binding membrane proteins (PBPs), which are in-40 
volved in the cross-linking of the bacterial cell wall. Interestingly, amoxicil-41 
lin is capable of reducing26 Au(III) to Au(0) and stabilizing the resulting 42 
AuNPs due to high affinity of the amino groups to the gold surface.  43 
Here we present the one-pot synthesis of amoxicillin-coated AuNPs 44 
(amoxi@AuNPs) that combined show enhanced photo-antimicrobial 45 
effect; i.e., highly reduced amount of antibiotic (typically 500 mg per dose 46 
are used), short irradiation time (~ 30 min) and high selectivity toward 47 
prokaryotic cells. Facile to prepare amoxicillin-coated AuNP were stable 48 
inside the bloodstream and tissue distribution, showing rapid clearance 49 
 from the organism at the same time. In this sense, they are a better option 1 
for clinical use in comparison to other stabilizing agents, such as glutathi-2 
one.27 Furthermore, we introduce a novel method to check the selectivity of 3 
the toxicity in a co-culture of bacteria and blood cells through time-resolved 4 
fluorescence microscopy.  5 
RESULTS AND DISCUSSION 6 
Synthesis and characterization of amoxi@AuNPs 7 
AuNPs were synthesized by thermal reduction utilizing amoxicillin 8 
as both reducing and stabilizing agent. The absorption spectrum 9 
(Figure 1) of the amoxi@AuNPs shows the characteristic plasmon 10 
band of small spherical nanoparticles centered around 540 nm, 11 
while the presence of a second absorption band around 950 nm can 12 
account for the plasmon absorption bands of more complex 13 
nanostructures, namely triangular, hexagonal and irregular polygo-14 
nal plates, including nanorods (see Figure S2-S4).28  15 
DLS measurements determined a hydrodynamic radius for the 16 
amoxi@AuNPs of 79 ± 43 nm. The broad distribution of particle 17 
sizes found by this technique is in agreement with the presence of 18 
larger non-spherical nanostructures; in contrast to the AuNPs 19 
synthesized with NaBH4 (‘unprotected’ AuNPs) that show a more 20 
monodisperse size distribution: 8 ± 2 nm. The positive Zeta poten-21 
tial value found for amoxi@AuNPs (+30 ± 7 mV) confirms the 22 
effectiveness of the amoxicillin as colloidal stabilizer. 23 
 24 
Figure 1. Normalized absorption spectra of unprotected AuNP (black) and 25 
of amoxi@AuNPs (red). The absorption wavelength at around 950 nm 26 
accounts for the presence of non-spherical nanostructures.  27 
The conjugation of the stabilizer agent to the nanoparticle was 28 
confirmed by FT-IR (see Figure S5). AuNPs showed ~11% amoxi-29 
cillin loading as determined by TGA. This amount is enough to 30 
stabilize the particle but it is very low compared to the daily dose 31 
administered to a patient (1-2 g) which could minimize all the 32 
amoxicillin side effects.29-30 33 
These new amoxi@AuNPs composites showed great stability in 34 
different media such as PBS 37.5, 25%, 12.5% y 7.5% for 72 h, and 35 
CMH 25% for 48 h, as well as CMH 12.5% and 7.5%; CTS 25%, 36 
12.5% and 7.5% for 168 h and Milli-Q water, for 96 h. (Figure S6). 37 
Nevertheless, they crashed immediately in all concentrated biologi-38 
cal media and PBS (100 and 50 %). Based on these findings, mi-39 
crobiological assays were carried out in 37.5 % PBS, which allows 40 
the bacteria to be metabolically active and does not interfere with 41 
the monitoring of the plasmon absorption. 42 
In vitro studies  43 
Antibacterial Activity 44 
Staphylococcus aureus ATCC 29213 (MSSA) and a methicillin-45 
resistant clinical isolate of Staphylococcus aureus (MRSA) were 46 
killed by 1.5 μg/mL amoxi@AuNPs after only 30 min of irradiation 47 
(Figure 2) with white light using an LED expo-panel (Figure S7). 48 
This is considerably faster than other nano-photosensitizers we 49 
have previously tested under similar exposure conditions.7, 10 It is 50 
worth noting that light itself does not produce any damage or 51 
change of the bacterial normal growth. The selection of white light 52 
irradiation was based on the broad absorption spectrum shown by 53 
the amoxi@AuNPs composites (Figure 1), ensuring the excitation 54 
of most of the nanostructures present in the solution. Interestingly, 55 
excitation using only green light (525 nm) did not produce antibac-56 
terial effect, thus the bactericidal effect requires the excitation of 57 
more complex nanostructures using the full visible spectrum. Addi-58 
tionally, amoxi@AuNPs were able to kill all the MSAA after 90 59 
minutes in the dark but not the MRSA. This could be a conse-60 
quence of the synergistic effect18, 31 between the antibiotic and the 61 
nanoparticle, as amoxicillin alone was not bactericidal at this low 62 
dose. It is important to highlight that the system temperature was 63 
kept at 37-38ºC during all the experimental procedures. Despite the 64 
constant bulk temperature, it is well known that the excitation of 65 
the surface plasmon of AuNPs can induce a localized heat on the 66 
particle surface. Thus, the high local temperature experienced by 67 
the bacteria in close proximity to the surface of the particle could 68 
trigger their death.32 In fact, gold nanoparticles are able to convert 69 
the absorbed light into heat very efficiently. These results in a hot 70 
lattice and the temperature could increase up to tens of degrees, 71 
enough to denaturalize biomolecules.33-35  72 
 73 
Figure 2. Bacterial growth over time of MSSA (A-B) and MRSA (C-D) 74 
samples treated under dark conditions (A-C) and under LED illumination 75 
(B-D) in the presence of 1.5 µg/mL of amoxi@AuNPs (red), 0.15 µg/mL 76 
amoxi@AuNPs (blue), and as control samples in the presence of amoxicil-77 
lin at the MIC (green) or PBS (black). 78 
ROS quantification in bacterial culture 79 
The generation of ROS was determined for samples of MRSA 80 
phototreated with amoxi@AuNP (at bactericidal concentrations). 81 
Figure 3 shows the maximum ROS production (almost 25 times 82 
basal level) quantified after just 10 min of irradiation. This level of 83 
ROS generation is even higher than the one observed for S. aureus 84 
treated with AuNP and light.10 A significant amount of ROS for-85 
mation (almost 17 times basal level) can be formed after 30 min of 86 
irradiation, although no bacterial growth was observed at that time. 87 
This could be due to the presence of some bacteria organelles and 88 
A B
C D
 structures which global integrity and functionality are too damage 1 
to keep bacteria alive. After 60 min, ROS production is negligible. 2 
Dark levels are almost null (not shown). The temperature of all the 3 
samples (including the irradiated ones) was kept at 37ºC during the 4 
whole experiment, avoiding the influence of macroscopic thermal 5 
effect. This significant amount of ROS detected could indicate that 6 
the bactericidal effect is in direct relation with the oxidative stress 7 
generated in bacteria when amoxi@AuNP (attached to their wall) 8 
are irradiated.  9 
 10 
Figure 3. ROS production for samples of MRSA phototreated with 11 
amoxi@AuNP (at bactericidal concentrations). 12 
Mammalian cell viability 13 
The 3T3 cell line has become the standard fibroblast cell line since 14 
Todaro and Green originally obtained them from Swiss albino 15 
mouse embryo tissue in 1962.36 32 This line correspond to immor-16 
talize cells; however, fibroblasts are much more sensitive to external 17 
factors than HeLa cells, most frequently used for in vitro experi-18 
ments. For this reason, the activity of its mitochondrial enzymes, as 19 
evaluated by MTT assay, is an important parameter for the analysis 20 
of the effects of new drugs on eukaryotic cells as it is a reflection of 21 
potential toxicity to mammals. Figure 4 shows the effect of free 22 
amoxicillin, bare AuNPs and amoxi@AuNPs at their antibacterial 23 
or photo-antibacterial concentrations. Our results suggest that the 24 
cell viability of the samples with antibiotic or nanoparticles is simi-25 
lar to control without drug (37.5 % PBS) and they all presented 26 
slightly less survival than the control with DMEM. Free amoxicillin 27 
was found to be non-toxic to other mammal cells in previous litera-28 
ture reports while our own studies described the biocompatibility 29 
of uncoated AuNPs.10, 37 30 
 31 
 32 
  33 
Figure 4. Cell survival (%) of fibroblast 3T3 treated with: 1.5 μg/mL 34 
amoxi@AuNP, 32 μg/mL amoxicillin, 37.5% PBS and DMEM, under 24 h 35 
of visible light irradiation (red) or under dark conditions (grey) for 24 h at 36 
37 °C, 5 % CO2 and 95 % humidity. 37 
Figure 4 shows that amoxi@AuNPs were not cytotoxic even under 38 
the same irradiation conditions used for the antimicrobial test. 39 
Similar results were found for gold nanoparticles embed in am-40 
phiphilic block copolymers.38 AuNPs are essentially harmless when 41 
compared to other antimicrobial nanoparticles, such as zinc nano-42 
particles, which have a substantial toxic impact to human fibroblast 43 
after 24 h.39 This demonstrates that the proposed photosensitizer is 44 
selectively toxic for bacteria and does not affect eukaryotic cells to 45 
any significant extent, due to the absence of any penicillin-binding 46 
protein 1A on the eukaryotic membrane. 47 
Parenteral and intraperitoneal injection of nanoparticles can pro-48 
duce high local concentration and broad distribution in the circu-49 
lating blood, leading to the need for evaluation of their biological 50 
safety. Ex vivo experiments on whole blood were conducted be-51 
cause erythrocytes together with other blood cells and serum con-52 
tent reflect properly the actual conditions in mammals organism.40 53 
Experiments were performed at t = 0, 2, 5 and 24 h in the dark and 54 
under LED irradiation, with the bactericidal concentration of 55 
amoxi@AuNP (1.5 μg/mL). Total hemolysis was established by 56 
adding H2O to the red blood cell (RBC) samples; n=3; SD<0.1. 57 
See Figure S7 for illumination details. The tested amoxi@AuNPs 58 
did not produce any alteration to the red blood cells, as shown in 59 
Table 1. There was no hemolysis at all, even under irradiation 60 
conditions. Thus, the amoxi@AuNPs are selectively toxic for bacte-61 
ria and do not affect erythrocytes. Under these illumination condi-62 
tions, the photo-thermal effect is then harmless for eukaryotic cells.  63 
Table 1. Hemolysis percentage (%) of blood samples treated 64 
with 1.5 μg/mL amoxi@AuNP and with 0.9 % NaCl as negative 65 
control and H2O as positive control 66 T	 Control	 Amoxi@AuNPs	
	
0	h	 1.3	 1.2	 1.2	 1.3	2	h	 1.3	 1.3	 1.3	 1.4	5	h	 1.2	 1.2	 1.2	 1.2	24	h	 1.3	 1.2	 1.2	 0.9	LED	 OFF	 ON	 OFF	 ON	
 67 
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Treatment
 In order to further prove that amoxi@AuNPs are selectively toxic 1 
for bacteria, co-cultures with blood cells were treated with the 2 
particles under the same irradiation conditions. The FLIM tech-3 
nique is extremely useful in bioimaging, where, for instance, light 4 
scattering can interfere with steady-state fluorescence imaging. The 5 
fluorescence lifetime can change depending on the fluorophore 6 
environment and hence the same fluorophore can be tracked in 7 
different locations utilizing the same emission wavelength. Here we 8 
use this technique together with a well-known DNA and RNA 9 
intercalator, acridine orange (AO-see Figure S8).41 Concentrations 10 
of AO around 0.3 mg/mL (1 mM) or higher lead to the formation 11 
of non-fluorescent dimers.42 However, AO can intercalate in nucle-12 
ic acid helices as the cationic monomer can presumably bind 13 
through electrostatic interaction with negatively charged phos-14 
phate. This interaction recovers the AO fluorescent properties and 15 
is the reason why AO is extensively used as a biological stain in 16 
fluorescence microscopy. When bound to ssDNA, AO shows a 17 
stable emission maximum at 630 nm upon excitation at around 458 18 
nm. Interestingly, AO, when externally bound to disorganized or 19 
broken genetic material is energetically less stable and is also very 20 
weakly emissive.43 Here, AO was found to bind to the genetic mate-21 
rial in both live bacteria and cells showing emission around 630 nm 22 
upon excitation at 440 nm. When the cells are subjected to damage, 23 
the genetic material of a dead cell is severely disrupted if not com-24 
pletely disintegrated. As a consequence, the AO most likely spreads 25 
into the solution as the non-fluorescent dimer forms or remains 26 
externally bound to the remaining DNA/RNA bases producing a 27 
weak and short emission. Interestingly, the lifetime of the emissive 28 
structures is different when the AO is attached to live bacteria (~3-29 
7 ns), live white blood cells (~7-14 ns), or bound externally to the 30 
disrupted genetic material of dying cells (<3 ns) with a lifetime 31 
almost as short as free AO.44 Thus, using time-resolved fluores-32 
cence techniques we were able to differentiate live bacteria or 33 
eukaryotic cells from dead ones.  34 
According to the lifetime color scale at the bottom of Figure 5, 35 
groups of S. aureus appeared bright green while alive (Figure 5-A) 36 
and the few dead coccus that are dead but were not completely 37 
broken by photothermal effect of PACT appeared blue (Figure 5-38 
B), indicating a decrease in the AO emission lifetime. Live erythro-39 
cytes (without nucleus or genetic material) were observed as pale 40 
green rings (Figure 5-C, D and E) and were not found heating in 41 
the control sample (Figure 5-F). The same sample presented a 98 42 
% of hemolysis in parallel measurements. Lymphocytes were ob-43 
served as bright yellow-orange spots when alive (Figure 5-C, D and 44 
E) and pale green spots when dying or damaged (Figure 5-F). A 45 
larger white blood cell (eosinophil) was observed alive (Figure 5-46 
E). Its nucleus appeared dull green because of the lax chromatin 47 
content; however, the AO presented longer lifetimes, up to 14 ns in 48 
the cytoplasm due its strong interaction with eosinophilic granules, 49 
described by Ueki et al45 and previously by Robbins et al.46 The 50 
aforementioned difference in the emission lifetime of AO was 51 
developed as a practical and fast method to study the survival of 52 
both eukaryotic and prokaryotic cells together. It requires just one 53 
fluorescent dye, one excitation laser and one emission filter, in 54 
contrast to other similar techniques that excite AO with different 55 
lasers and need other fluorescent dyes as ethidium bromide or 56 
propidium iodide as contrast agents.47-48 57 
 
  
Figure 5. FLIM images of biological samples containing AO: co-culture of MSSA and blood cells treated with amoxi@AuNP for 30 min in darkness conditions 
(C) and under irradiation (D), S. aureus suspension treated with amoxi@AuNP for 30 min in darkness conditions (A) and under irradiation (B), blood cells 
treated with amoxi@AuNP for 30 min in darkness conditions (E) and heated at 80 °C (F). Color gradient bar at the bottom indicates lifetime of AO emission 
in ns. Scale bar: 20 µm. 
In vivo studies The distribution of the nanoparticles in internal organs is crucial to 
determine their in vivo stability and fate after the desired activity is 
 completed. Following IP injection (see experimental section), 
amoxi@AuNPs were found using TEM analysis (Figure 6) inside 
the liver (rows A and B), the kidney (rows C and D) and the spleen 
(rows E and F). Importantly, they did not go through the brain 
blood barrier as amoxi@AuNPs were not found in brain tissue 
(data not shown). In general, the nanoparticles were internalized in 
vesicles in Kupffer cells in the liver just 2 h after IP injection. Usual-
ly, hepatobiliary system represents the main route of excretion for 
particles that do not undergo renal clearance.49 Nanoparticles of 
diameter equal of less than 100 nm, smaller than the pore size of 
liver fenestrae, could have easily penetrated through the endothelial 
wall too. At the same time, some amoxi@AuNPs were found in the 
spleen, indicating that they had been carried there earlier by the 
phagocytic cells. However, for these nanoparticles our results indi-
cate that the largest NPs amount was found in the kidneys (2 h post 
injection) being internalized in vesicles after having gone through 
the microvilli. Only a small fraction of the nanoparticles was found 
in the samples taken 5 h after administration. This could be due to 
the elimination in urine (vide infra) or as result of normal process 
of vesicle degradation, since shrunken vesicles were observed 
(Figure 6-IIIC/IIID). In kidneys and the spleen, where a few nano-
particles were interacting with the dense chromatin, around 5 % of 
pyknotic nuclei were observed (n=1008 cells), possibly as a conse-
quence of the oxidative-stress generated by the nanomaterial.50 It is 
noteworthy that after 24 h, all three organs presented normal histo-
pathology. Their different composing cells (including hepatocytes, 
epithelial and endothelial cells, podocytes, macrophages and red 
and white blood cells) looked unaltered and were of normal size 
and structure. The AuNP without antibiotic stabilization were only 
found in small quantities in the liver at 2 h, indicating their poor 
stability in biological fluids after injection. According to our results, 
coating of AuNP is necessary to improve their in vivo stability. To 
obtain a global characterization, 2 grids were prepared per each 
organ (2 organs per each condition) and over 300 TEM pictures 
were taken. The more representative ones were selected to illus-
trate the path of the nanoparticles through the tissues studied 
(Figure 6). 
 
  
Figure 6. Representative TEM pictures of rat tissue samples showing the biodistribution of amoxi@AuNPs in the liver (rows A and B), kidneys (rows C and 
D) and spleen (rows E and F) after intraperitoneal injection. Scale bar is the same (1 µm) for all pictures. 
Additionally, particles larger than the effective pore size in normal 1 
intact endothelium (5 nm), such as those used here, experience 2 
prolonged circulatory times due to slow transportation across the 3 
endothelium; therefore, the study of their effect on blood cells is 4 
quite relevant. Cell counting (Table 2) on samples of rats injected 5 
with nanoparticles (Group I and Group II) was not different from 6 
the control animals (Group III), except for a slight increase in the 7 
number of neutrophils (10 % over top reference value, p < 0.05) in 8 
Group II at 2 h. This is correlated with the observation of active 9 
phagocytic cells in the liver, kidneys and spleen at the same time. 10 
The elevation in neutrophils may be due to the host response to the 11 
injection and distribution of amoxi@AuNPs. Normal values were 12 
totally restored after 24 h, as a sign of complete elimination of the 13 
nanoparticles from the organism. According to microscope obser-14 
 vation of smears, red blood cells from Group I and II kept their 1 
integrity, suggesting that they were not stressed by the nanomateri-2 
al. This finding is in agreement with the ex vivo hemolysis test 3 
results. 4 
Table 2. Cell counting (%) from blood smears of rats treated 5 
with AuNP (I), amoxi@AuNP (II) and physicological saline 6 
solution (III).  7 
 
2 h 5 h 24 h 
% Ref* I II III I II III I II III 
N 1--16 18 26 5 12 16 6 10 11 6 
L 82-96 82 74 94 86 82 93 89 87 92 
M 0-3 0 0 1 2 2 0 0 2 2 
E 0-2 0 0 0 0 0 1 1 0 0 
B 0 0 0 0 0 0 0 0 0 0 
S.N 0-1 0 0 0 0 0 0 0 0 0 
* “Ref” are the reference values for healthy male Wistar rats. 8 
N (neutrophils), L (lymphocytes), M (monocytes), E (eosino-9 
phils), B (basophils), SN (segmented neutrophils). 10 
Finally, renal excretion is the desirable pathway for AuNP removal, 11 
because it would keep the catabolism or breakdown to a minimum, 12 
avoiding possible side effects.49 Renal clearance, as a fundamental 13 
part of drug elimination is determined by the molecular chemical 14 
and physical properties, including size, surface charge, and surface 15 
chemistry.51 Without such clearance or their biodegradation into 16 
biologically benign components, the toxicity potential increases. To 17 
address this concern, qualitative detection of intact nanoparticles in 18 
urine was done by measuring their plasmon absorption (Figure 7). 19 
Urine samples from Group II showed an absorption peak  (abs < 20 
0.40) at 540 nm, consistent with spherical AuNP after 5 h of IP 21 
injection. Apparently, other shapes and sizes would preferably be 22 
up-taken by cells and degraded inside vesicles as shown in TEM 23 
pictures. It seems that most of the nanomaterial is being eliminated 24 
between 2-5 h after injection, because the plasmon peaks are not 25 
bigger in urine samples collected after one day of injection than in 26 
those collected after 5 h; in agreement with previous report 52 Both 27 
works suggest that the kidneys are the primary sites for clearance of 28 
the smallest particles, followed by the hepatobiliary system. No 29 
bare AuNP were found in urine collected from Group I, supporting 30 
the hypothesis that uncoated AuNP are not being well distribut-31 
ed/eliminated. In summary, amoxicillin is not only helping to the 32 
stabilization of the nanoparticles, but also to their renal clearance.  33 
 34 
Figure 7. Absorption spectra of amoxi@AuNPs from rat urine collected 35 
after 5 h (blue) and 24 h (red) of IP injection and resuspended in 37.5 % 36 
PBS. 37 
CONCLUSIONS 38 
The combination of in vivo and in vitro studies presented here 39 
showed that amoxi@AuNPs are suitable nanostructures for PACT 40 
applications. amoxi@AuNPs can be easily synthesized in one pot 41 
utilizing amoxicillin as both reducing and stabilizing agent. The 42 
particles are stable in biological media and show photoinduced 43 
antibacterial activity (irradiation time ~30 min), even against AR 44 
strains. Importantly, amoxi@AuNPs are very biocompatible with 45 
eukaryotic cells under PACT conditions. The bacterial death is 46 
believed to occur upon localized surface plasmon excitation of the 47 
AuNP. The antibiotic was used as a reducing agent for the synthesis 48 
of AuNPs and its presence confers the NP with the selectivity 49 
toward the bacterial cell. This is a major advantage when combat-50 
ing microorganism that produce lytic enzymes, developing antibi-51 
otic resistance. Accordingly, the amoxi@AuNPs can act faster than 52 
silver and zinc nanoparticles tested by other groups without plas-53 
mon excitation,53 showing their potential as antibacterial agents.  54 
We have also demonstrated that FLIM can be very useful to deter-55 
mine the cell selectivity and bactericidal activity in prokaryot-56 
ic/eukaryotic co-cultures by a rapid and simple analysis. This analy-57 
sis only requires one fluorescent dye, one excitation laser and one 58 
emission filter, in contrast to similar techniques that excite AO with 59 
different lasers and need other fluorescent dyes as ethidium bro-60 
mide or propidium iodide as contrast agents.  61 
Finally and yet importantly, our results show that the injected 62 
AuNP have a faster clearance rate than other similar 63 
nanomaterials54-55 and have not induced considerable cytotoxicity 64 
responses. As a result, amoxi@AuNPs seem to have a low potential 65 
of accumulation in mammal organisms. These findings are remark-66 
ably useful for the potential development of pharmaceutical formu-67 
lations. 68 
EXPERIMENTAL SECTION 69 
Materials 70 
Tetrachloroauric acid-99% (HAuCl4) was purchased from Sigma-71 
Aldrich, Trihydrate Amoxicillin from Todo Droga, (Argentina). Mueller 72 
Hinton broth (MHB), Tryptic Soy broth (TSB), Tryptic Soy agar (TSA), 73 
Brain Heart infusion (BHI), Luria Bertani broth (LBB) and Phosphate 74 
Buffer Saline (PBS) were purchased from Britania (Argentina).  75 
Synthesis of amoxi@AuNPs and AuNP 76 
Antibiotic coated nanoparticles were prepared with amoxicillin in one-77 
step synthesis that uses the antibiotic as both the reducing and stabilizer 78 
agent. This bottom-up method is based on the reduction of the gold pre-79 
cursor (HAuCl4 100 µL, 10 mM) with amoxicillin trihydrate (900 µL, 0.1 80 
mM) at 50 °C for 18 minutes. This corresponds to a 16 wt% of amoxicillin 81 
with respect of the mass of Au. All solutions were freshly prepared prior to 82 
the synthesis and left to stabilize at room temperature for 30 minutes 83 
before heating. Three cycles of Milli-Q water washing and centrifugation 84 
were used to remove unbound amoxicillin molecules.  85 
In order to obtain 500 mL of 0.2 mM bare AuNP, 1 mL of 0.1 M 86 
HAuCl4 aqueous solution was added to 500 mL of previously cooled Milli-87 
Q water (8 °C). Then, 10 mL of a NaBH4 (0.13 M) solution was trans-88 
ferred dropwise to the flask.  89 
Characterization of amoxi@AuNP 90 
The changes of the surface plasmon resonance of the resuspended pellet 91 
and the absorption spectrum of the amoxicillin molecules present in the 92 
supernatant were monitored using a Cary 60 UV-Vis spectrophotometer. 93 
Shape and size of the synthesized AuNP were preformed through Trans-94 
mission Electron Microscopy (TEM-Jeol 1200 EX II). Samples for TEM 95 
measurements were prepared by placing a 4 µL drop of the amoxi@AuNP 96 
solution on carbon-coated copper grids and left to dry completely at 37 °C 97 
in a drying oven. At least 400 nanoparticles were analysed statistically using 98 
ImageJ software. On the same samples, zeta potential and dynamic light 99 
scattering (DLS) were measured with a Malvern Zetasizer (model Nano-100 
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 S). The binding of amoxicillin to AuNP was analyzed by Fourier Transform 1 
Infrared (FT-IR) spectroscopy in transmission mode using a Nicolet iN 10 2 
spectrophotometer. Samples of amoxicillin trihydrate, bare AuNP and 3 
amoxi@AuNPs were freeze-dried and then measured by FT-IR at low 4 
temperature. 5 
The amount of amoxicillin was determined by Thermogravimetric 6 
Analysis (TGA). For this, 4 mL of 1.5 μg/mL of the amoxi@AuNPs were 7 
centrifuged down and pellets were combined to be exhaustively dried in a 8 
desiccator for 48 h prior to TGA at 10 °C/min from 25 to 1000 °C under 9 
nitrogen atmosphere (flow rate of 25 mL/min) with a TA-THA Q5000.  10 
Colloidal stability  11 
Stability measurements of amoxi@AuNPs (1.5 μg/mL) in different 12 
buffer solutions and growth media were conducted based on the change in 13 
plasmon absorbance maxima at different time points, utilizing UV-Vis 14 
spectrophotometry. Stability was considered as the time it took for a 20% 15 
decrease in plasmon absorption at the wavelength on the initial maximum 16 
absorbance.8 The stability measurements were carried out (using a Biotek 17 
plate reader) for 7 days (time = 0, 0.5, 1, 2, 4, 6, 12 18, 24, 48, 72, 120, 144, 18 
168 h) in Milli-Q water, saline solution, PBS buffer solution (pH=7), 19 
Mueller Hinton Broth (MHB) and Tryptic Soy Broth (TSB) at different 20 
concentrations (100, 50, 25, 12.5 %). In order to avoid contamination, the 21 
stability measurement of nanoparticles dispersed in growth media were 22 
conducted under sterile conditions. 23 
Bacterial strains and growth conditions 24 
The experiments were performed using Staphylococcus aureus ATCC 25 
29213 (MSSA ATCC 29213) and a methicillin-resistant clinical isolate of 26 
Staphylococcus aureus (MRSA 9455). Clinical isolate was supplied by the 27 
Bacteriology Service of Sanatorio Aconcagua, Córdoba, Argentina. Stock 28 
cultures were maintained in TSB and stored in a freezer in 10% glycerol. 29 
Antibacterial Capacity 30 
Antibacterial activity of novel amoxi@AuNPs against MSSA and MRSA 31 
was tested. Bacterial suspensions of 106 colony forming units per mL 32 
(CFU/mL) in 37.5% PBS (pH=7) from a single colony of each strain were 33 
prepared. Using a 96 well plate, 100 µL of bacterial suspension and 100 µL 34 
of the tested solutions (37.5% PBS, 0.15 μg/mL, amoxi@AuNPs, 1.5 35 
μg/mL amoxi@AuNPs and amoxicillin at minimum inhibitory concentra-36 
tion (MIC) per each strain as control: 2 μg/mL for MSSA and 32 μg/mL 37 
for MRSA) were mixed and irradiated for a total of 90 min under white 38 
LED illumination at 37 °C. Control experiments were run under the same 39 
conditions in the dark. All samples were run in triplicates. Aliquots of each 40 
sample were diluted properly and seeded in TSA plates. CFU were counted 41 
from the agar after 24 h of incubation at 37 °C. 42 
incubation at 37 °C. 43 
ROS quantification in bacterial culture 44 
The pre-fluorescent probe dihydrorhodamine 123 (DHR) was chosen 45 
for its high sensitivity to quantify total ROS and Reactive nitrogen species 46 
(RNS).56 This dye diffuses passively through most of cell membranes, 47 
where DHR generates a fluorescent green signal at 536 nm when oxidized. 48 
Radical indicators of oxidative stress were measured with DHR (1 µM) in 49 
bacterial suspensions (109 CFU/ml) treated with a 1.5 µg/mL of 50 
amoxi@AuNPs. Samples were irradiated for 10, 30, 60 and 90 min.  51 
 52 
Cell Viability 53 
The 3T3 fibroblasts were cultured in Dulbecco Modified Essential Me-54 
dium (DMEM) with 10 % calf serum. Cells were grown until 85% to 95% 55 
confluence, then washed with phosphate-buffer saline (Invitrogen) and 56 
trypsinized with 1 mL of 0.05% trypsin, 0.53 mM ethylenediaminetet-57 
raacetic acid, phenol red. Trypsinization was stopped by adding fresh 58 
medium to the reaction. The cells were washed twice by centrifugation with 59 
DMEM without serum, resuspended in medium without serum and plated 60 
at approximately 105 cells/per well after proper cell counting in an Im-61 
proved Neubauer chamber. They were incubated overnight to allow at-62 
tachment and then treated with 1.5 μg/mL amoxi@AuNP, 32 μg/mL 63 
amoxicillin, 37.5% PBS and DMEM and irradiated with a white LED for 24 64 
h. Cells were kept in the dark for 24 h at 37 °C, 5 % CO2 and 95 % humidity. 65 
MTT assay based on the reduction of tetrazolium salt to formazan crystals 66 
in living cells was done according to a Sigma protocol to determine the 67 
percent survival.57 The absorbance spectra on the different wells were 68 
measured using a Biotek plate reader. 69 
Hemolysis 70 
The integrity of red blood cells from human healthy volunteers (from 71 
Córdoba, Argentina) incubated with amoxi@AuNPs 1.5 µg/mL with and 72 
without irradiation, was evaluated following a procedure previously de-73 
scribed58 with slight modifications. The amoxi@AuNPs had to be removed 74 
by centrifuging the samples before reading the absorbance of the free 75 
hemoglobin (541 nm) to avoid spectral interference. Measurements were 76 
made at 0, 2, 5 and 24 h by triplicates. An aqueous solution of 0.9% NaCl 77 
and H2O were used as negative and positive control of hemolysis, respec-78 
tively. 79 
Fluorescence Lifetime Imaging Microscopy (FLIM) study on co-80 
cultures of blood cells and bacteria 81 
Acridine orange (AO) was employed due to its characteristic fluores-82 
cence emission when intercalated in DNA or RNA.59-60 FLIM imaging of 83 
the dye was introduced as a method to check the viability of blood cells 84 
(anticoagulated fresh samples from healthy volunteers from University of 85 
Córdoba) and bacteria (107 CFU/mL of S. aureus 29213) cultured togeth-86 
er and treated with irradiated and non-irradiated amoxi@AuNPs (1.5 87 
ug/mL). The samples were studied using a Fluorescent Lifetime Imaging 88 
System (FLIM, PicoQuant Microtime 200). The instrument is equipped 89 
with a frequency doubled picosecond pulse diode laser (440 ± 10) nm, 70 90 
ps, 40 MHz, LDH-D-C-440, PicoQuant). The laser beam was collimated 91 
and focused through a fiber-coupling unit. A beam splitter Z440 bcm 92 
(Chroma) was used to reflect the excitation light into the oil immersion 93 
TIR (total internal reflection) objective (100×, NA1.45, Olympus, 94 
PLAPO). The excitation dose (average power) is about 0.6 mW for all 95 
samples. Emission was collected between 610-680 nm using the 96 
ET645/75BP emission filter. Briefly, 100 μL of the biological sample and 97 
100 µL of AO (1 mg/mL) were mixed and incubated at room temperature 98 
for 5 minutes. Lifetimes longer than 5 ns were found for live bacteria and 99 
cells, while dead bacteria or cells can be detected by a decrease in the 100 
emission intensity and lifetime of unbound AO produced by disorganiza-101 
tion of the spread genetic material in necrotic or broken cells. Aliquots of 102 
the dye alone or mixed with amoxi@AuNPs were also tested for fluores-103 
cence. Fresh samples of blood cells or PBS suspension of bacteria in the 104 
absence of nanoparticles were run as controls for “alive samples”. Accord-105 
ingly, the same samples were also heated up to 80 °C and imaged as “dead 106 
samples control”. Furthermore, bacterial growth in the observed samples 107 
was also ruled out by CFU counting in MH agar plates while integrity of 108 
eukaryotic cells was monitored by parallels hemolysis measures. 109 
Biodistribution of nanoparticles  110 
Male Wistar rats with a body weight of 280-310 g at the time of drug 111 
administration, were maintained in the animal house facility at the Depar-112 
tamento Farmacología, Córdoba, Argentina (Food and water provided ad 113 
libitum at a constant temperature 22 ± 2 °C with 12 h by 12 h light and dark 114 
cycle). The rats were handled for one week for acclimatization. At the 115 
beginning, the rats were divided into 3 groups of 2 rats each: Group I was 116 
subjected to intra-peritoneal injection with 34 μg/mL AuNP, Group II with 117 
1.5 μg/mL amoxi@AuNPs and Group III with physiological saline solution 118 
as control. After 2, 5, and 24 h post-injection, two animals from each group 119 
were anaesthetized using a mix of 55 mg/kg ketamine and 11 mg/kg 120 
xylazine. Immediately, cardiac perfusion with PBS (0.1 M) was carried out 121 
to remove all red blood cells from their internal organs. Finally, after proper 122 
fixation (35 minutes of perfusion with 2 % paraformaldehyde and 2 % 123 
glutaraldehyde in PBS) the liver, heart, kidney, spleen, and brain were 124 
harvested. TEM pictures were taken with a TEM-Zeiss-Leo 906E micro-125 
scope. All experiments on animals were conducted complying the ARRIVE 126 
guidelines and were carried out in accordance with the National Institutes 127 
of Health guide for the care and use of Laboratory animals (NIH Publica-128 
tions No. 8023, revised 1978) and the Guide for the Care and Use of 129 
Laboratory Animals (Eighth Edition, 2011).61 130 
Biocompatibility with blood cells 131 
Previous to perfusion, blood smears (triplicates) were made from fresh 132 
blood extracted through a cardiac puncture.62 Samples were stained with 133 
May Grunwald/Giemsa and analyzed under an optical microscope.  Results 134 
reported are the averages of quadruplicates. Student t-test was performed 135 
 to detect differences that were considered statistically significant when P 1 
values were lower than α=0.05. 2 
Renal clearance 3 
At the same time intervals (2, 5 and 24 h), urine was collected using 4 
metabolic boxes. The plasmon absorption of the AuNP was measured by 5 
spectroscopy using a multi-well spectrophotometer (Biotek), by centrifug-6 
ing the collected urine and resuspending the pellet in 0.5 mL of 37.5 % PBS. 7 
 8 
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